Thereafter, a monoclonal antibody called ATN-658 was developed to target the human uPAR protein, and administration of the ATN-658 antibody significantly reduced the growth, invasiveness, and metastatic ability of prostate cancer cells both in vitro and in vivo [106]. The gene discussed is PLAUR; the disease is prostate carcinoma.